Safety of vancomycin in patients with moderate and severe renal dysfunction

Aim: The new guidelines in Japan do not recommend a vancomycin (VCM) loading dose for patients with an estimated glomerular filtration rate (eGFR) 30 < and <= 80 mLxmin(-1)x1.73m(-2) (moderate renal dysfunction) or administration to those with the eGFR < 30 mLxmin(-1)x1.73m(-2) (severe renal dysfunction). We investigated the safety and efficiency of VCM in patients with moderate and severe renal dysfunction based on the new guidelines. Materials and methods: The study involved patients admitted to our hospital between April 2014 and March 2018 with an eGFR < 80 mLxmin(-1)x1.73m(-2) and treated with VCM. VCM trough concentration and pre- and post-administration renal function were investigated retrospectively. The primary endpoints were the proportion of patients who achieved an effective trough concentration of 10 - 20 mu g/mL and rate of acute kidney injury (AKI). Results: We included 64 patients (32 moderate, 32 severe). The mean VCM trough concentration achieved for the first time was 9.3 and 11.6 mu g/mL in the moderate and severe renal dysfunction groups, respectively (p = 0.91). The effective trough concentration endpoint was achieved by 50% and 43% of the patients in the severe and moderate renal dysfunction groups, respectively, and no significant difference was found in the AKI rate. The serum creatinine change was significantly different between the groups - the moderate group showed a slight deterioration and the severe renal dysfunction group an improvement. Conclusion: It may be necessary to increase the dose for these patients with severe renal dysfunction while implementing a VCM loading dose and monitoring trough concentrations and adverse effects.